Business & Regulation

The players and chips are ready, what can poker teach us about the biosimilars business?

Big pharma CEOs should be wary of because orphans are usually better off alone.

Sitting Down With... Carol Lynch, Global Head Biopharmaceuticals, Sandoz.

The EMA says “yes” to transparency, but some pharma companies have other ideas.

A consortium of vendors and pharma companies search for a single, serialization standard.

Are reduced GDUFA fees on the horizon for contract manufacturers?

The original goal of 'Obamacare' was to increase access to health insurance, but has it worked?

Robust formulation and coating expertise are required to get the best results with continuous coating.

With an approaching patent cliff in biologics, are we be about to see a rise in litigation?

PhRMA explain why the US Elections are important for the pharma industry.